Abstract
Breast cancer ranks among the most prevalent cancers in women globally, with its treatment efficacy heavily reliant on the early identification and diagnosis of the disease. The importance of early detection and diagnosis cannot be overstated in enhancing the survival prospects of those afflicted with breast cancer. With the increasing application of machine learning technology in the medical field, algorithm-based diagnostic tools provide new possibilities for early prediction of breast cancer. In this study, we introduced a novel feature selection approach, which leverages Shapley additive explanation (SHAP) values as the basis for Recursive Feature Elimination (RFE), utilizing a Random Forest (RF) algorithm within the RFE framework. To address the data imbalance challenge, we incorporated Borderline-SMOTE1. The efficacy of the proposed method was assessed using five machine learning models, K-Nearest Neighbor (KNN), Random Forest (RF), Logistic Regression (LR), Support Vector Machine (SVM), and Light Gradient Boosting Machine (LightGBM), applied to the Wisconsin Breast Cancer Diagnosis (WBCD) datasets. Optimizing hyperparameters of five models using the Particle Swarm Optimization (PSO) algorithm. In the datasets, 26 features were filtered using our recommended algorithm, the LightGBM-PSO model demonstrated an outstanding performance. The model demonstrated an impressive accuracy of 99.0% in differentiating between benign and malignant cases, boasting a specificity and precision of 100%, a recall rate of 97.40%, an F-measure of 98.68%, an AUC of 0.9870, and a 10-fold cross-validation accuracy of 0.9808. Subsequently, we developed a corresponding online tool (https://breast-cancer-prediction-tool-cgbjlhkns7yig6bmzvztmc.streamlit.app/) based on this model for predicting the risk of breast cancer. Feature selection using recommended algorithm and optimization of the LightGBM model through PSO can significantly enhance the accuracy of breast cancer prediction. This could potentially improve the prognosis for patients diagnosed with breast cancer.